Heterocyclic compound based on N
View Patent ↗Heterocyclic derivatives based on N 6 -substituted adenine of, e.g.,a formula: wherein R2 is hydrogen, R6 is R6′-X, X is —NH—, and R6′ is substituted phenyl or substituted benzyl. The derivatives possess anticancer, mitotic, imunosuppressive and antisenescent properties for plant, animal and human cells, and methods of their preparation are disclosed. Included are also pharmaceutical compositions, cosmetic preparations and growth regulators, which contain these derivatives as active compound and the use of these derivatives for the preparation of drugs, cosmetic preparations, in biotechnological processes, in cosmetics and in agriculture.
1. An ageing- and senescence-inhibiting cosmetic composition comprising a heterocyclic compound based on N6-substituted adenine of the formula I
and the pharmaceutically acceptable salts thereof, wherein
R2 is hydrogen,
R6 is R6′-X,
wherein X is —NH—;
R6′ is substituted phenyl or substituted benzyl,
whereas the generic substituent groups have meanings identical with the definitions of the corresponding groups as defined in this legend, wherein
“substituted phenyl” refers to phenyl group which is substituted with one to five hydroxy and alkoxy groups, one to five hydroxy and halogen groups, one to five hydroxy and alkyl groups or one to five amino and halogen groups as defined herein,
“substituted benzyl” refers to the phenylmethyl group, wherein the phenyl group is substituted with one to five hydroxy and alkoxy groups, one to five hydroxy and halogen groups, one to five hydroxy and alkyl groups or one to five amino and halogen groups as defined herein,
whereas the generic substituent groups have meanings identical with the definitions of the corresponding groups as defined in this legend, wherein
“halogen” refers to fluorine, bromine, chlorine and iodine atoms;
“hydroxyl” refers to the group —OH;
“alkyl” refers to branched or unbranched C 1 -C 6 saturated chain being selected from the group consisting of methyl, propyl, isopropyl, tert-butyl;
“alkoxy” denotes the group —OR, wherein R is alkyl as defined herein;
and the racemates, optical isomers or acid salts thereof, including a pharmaceutical carrier.
2. An ageing- and senescence-inhibiting cosmetic composition which contains a heterocyclic compound based on N 6 -substituted adenine of the formula I according to claim 1 wherein the compound is selected from 6-(2-hydroxy-4-chlorobenzylamino)purine, 6-(2-hydroxy-5-chlorobenzylamino)purine, 6-(2-hydroxy-6-chlorobenzylamino)purine, 6-(2,3-dihydroxy-4-methoxybenzylamino)purine, 6-(2,5-dihydroxy-4-methoxybenzylamino)purine, 6-(2,6-dihydroxy-3-methoxybenzylamino)purine, 6-(2,5-dihydroxy-3-methoxybenzylamino)purine, 6-(2,6-dihydroxy-4-methoxybenzylamino)purine, 6-(2,3-dihydroxy-4-chlorobenzylamino)purine, 6-(2,5-dihydroxy-4-chlorobenzylamino)purine, 6-(2,6-dihydroxy-4-chlorobenzylamino)purine, 6-(2,6-dihydroxy-3-chlorobenzylamino)purine, 6-(3-hydroxy-4-methoxybenzylamino)purine, 6-(2-hydroxy-3-methoxybenzylamino)purine, 6-(4-hydroxy-3-methoxybenzylamino)purine, 6-(2-hydroxy-4-methoxybenzylamino)purine, 6-(4-hydroxy-2-methoxybenzylamino)purine, 6-(2-hydroxy-5-methoxybenzylamino)purine, 6-(3-hydroxy-4-methoxybenzylamino)purine, 6-(4-hydroxy-3-methoxybenzylamino)purine, 6-(2-hydroxy-6-methoxybenzylamino)purine, 6-(3-hydroxy-5-methoxybenzylamino)purine, 6-(2,6-dimethyl-4-hydroxybenzylamino)purine, 6-(3,5-dimethyl-4-hydroxybenzylamino)purine, 6-(2-amino-6-chlorobenzylamino)purine, 6-(3-amino-4-chlorobenzylamino)purine, 6-(2-amino-3-chlorobenzylamino)purine, 6-(2-amino-4-chlorobenzylamino)purine, 6-(2-amino-6-chlorobenzylamino)purine, 6-(2,6-diamino-3-chlorobenzylamino)purine, 6-(2,6-diamino-4-chlorobenzylamino)purine, 6-(4-amino-3-chlorobenzylamino)purine, 6-(4-hydroxy-2-methylanilino)purine, 6-(5-chloro-2-hydroxyanilino)purine, 6-(3-chloro-5-aminoanilino)purine, 6-(3-amino-4-chloroanilino)purine, 6-(3-chloro-4-aminoanilino)purine, including a pharmaceutical carrier.
3. A method for inhibiting ageing and senescence of mammalian epidermal cells, said method comprising administering to a mammal in need of such treatment an ageing- and senescence-inhibiting cosmetic composition comprising a heterocyclic compound based on N6-substituted adenine of the formula I
and the pharmaceutically acceptable salts thereof, wherein
R2 is hydrogen,
R6 is R6′-X,
wherein X is —NH—;
R6′ is substituted phenyl or substituted benzyl,
whereas the generic substituent groups have meanings identical with the definitions of the corresponding groups as defined in this legend, wherein
“substituted phenyl” refers to phenyl group which is substituted with one to five hydroxy and alkoxy groups, one to five hydroxy and halogen groups, one to five hydroxy and alkyl groups or one to five amino and halogen groups as defined herein,
“substituted benzyl” refers to the phenylmethyl group, wherein the phenyl group is substituted with one to five hydroxy and alkoxy groups, one to five hydroxy and halogen groups, one to five hydroxy and alkyl groups or one to five amino and halogen groups as defined herein,
whereas the generic substituent groups have meanings identical with the definitions of the corresponding groups as defined in this legend, wherein
“halogen” refers to fluorine, bromine, chlorine and iodine atoms;
“hydroxyl” refers to the group —OH;
“alkyl” refers to branched or unbranched C 1 -C6 saturated chain being selected from the group consisting of methyl, propyl, isopropyl, tert-butyl;
“alkoxy” denotes the group —OR, wherein R is alkyl as defined herein;
and the racemates, optical isomers or acid salts thereof, including a pharmaceutical carrier.
4. A method for inhibiting ageing and senescence of mammalian epidermal cells, said method comprising administering to a mammal in need of such treatment an ageing- and senescence-inhibiting cosmetic composition comprising a compound selected from 6-(2-hydroxy-4-chlorobenzylamino)purine, 6-(2-hydroxy-5-chlorobenzylamino)purine, 6-(2-hydroxy-6-chlorobenzylamino)purine, 6-(2,3-dihydroxy-4-methoxybenzylamino)purine, 6-(2,5-dihydroxy-4-methoxybenzylamino)purine, 6-(2,6-dihydroxy-3-methoxybenzylamino)purine, 6-(2,5-dihydroxy-3-methoxybenzylamino)purine, 6-(2,6-dihydroxy-4-methoxybenzylamino)purine, 6-(2,3-dihydroxy-4-chlorobenzylamino)purine, 6-(2,5-dihydroxy-4-chlorobenzylamino)purine, 6-(2,6-dihydroxy-4-chlorobenzylamino)purine, 6-(2,6-dihydroxy-3-chlorobenzylamino)purine, 6-(3-hydroxy-4-methoxybenzylamino)purine, 6-(2-hydroxy-3-methoxybenzylamino)purine, 6-(4-hydroxy-3-methoxybenzylamino)purine, 6-(2-hydroxy-4-methoxybenzylamino)purine, 6-(4-hydroxy-2-methoxybenzylamino)purine, 6-(2-hydroxy-5-methoxybenzylamino)purine, 6-(3-hydroxy-4-methoxybenzylamino)purine, 6-(4-hydroxy-3-methoxybenzylamino)purine, 6-(2-hydroxy-6-methoxybenzylamino)purine, 6-(3-hydroxy-5-methoxybenzylamino)purine, 6-(2,6-dimethyl-4-hydroxybenzylamino)purine, 6-(3,5-dimethyl-4-hydroxybenzylamino)purine, 6-(2-amino-6-chlorobenzylamino)purine, 6-(3-amino-4-chlorobenzylamino)purine, 6-(2-amino-3-chlorobenzylamino)purine, 6-(2-amino-4-chlorobenzylamino)purine, 6-(2-amino-6-chlorobenzylamino)purine, 6-(2,6-diamino-3-chlorobenzylamino)purine, 6-(2,6-diamino-4-chlorobenzylamino)purine, 6-(4-amino-3-chlorobenzylamino)purine, 6-(4-hydroxy-2-methylanilino)purine, 6-(5-chloro-2-hydroxyanilino)purine, 6-(3-chloro-5-aminoanilino)purine, 6-(3-amino-4-chloroanilino)purine, 6-(3-chloro-4-aminoanilino)purine, including a pharmaceutical carrier.
5. A method of claim 3 , wherein the mammalian epidermal cells are fibroblasts.
6. A method of claim 4 , wherein the mammalian epidermal cells are fibroblasts.